Mechanisms and management of diabetic painful distal symmetrical polyneuropathy

Diabetes Care

Volumn 36, Issue 9, 2013, Pages 2456-2465

  Tesfaye, Solomon ^a   Boulton, Andrew J M ^b   Dickenson, Anthony H ^c  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CARBAMAZEPINE; DULOXETINE; GABAPENTIN; IMIPRAMINE; LIDOCAINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; POTASSIUM CHANNEL; PREGABALIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SODIUM CHANNEL NAV1.3; SODIUM CHANNEL NAV1.7; SODIUM CHANNEL NAV1.8; THIOCTIC ACID; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; VOLTAGE GATED CALCIUM CHANNEL;

ARTICLE; BLURRED VISION; BODY WEIGHT DISORDER; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; CONSCIOUSNESS DISORDER; CONSTIPATION; DECREASED APPETITE; DIABETES EDUCATION; DIABETIC FOOT; DIABETIC NEUROPATHY; DIABETIC PAINFUL DISTAL SYMMETRICAL POLYNEUROPATHY; DIAGNOSTIC TEST; DISEASE PREDISPOSITION; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; EVENING DOSAGE; FOOT CARE; GAIT DISORDER; HEADACHE; HIGH RISK PATIENT; HUMAN; LOW DRUG DOSE; MEDICAL HISTORY; MONOTHERAPY; NAUSEA; NERVE CONDUCTION; NEUROPATHOLOGY; NONHUMAN; ORTHOSTATIC HYPOTENSION; PAIN ASSESSMENT; PAIN PARAMETERS; PATHOPHYSIOLOGY; PATIENT EDUCATION; PERIPHERAL EDEMA; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; QUALITY OF LIFE; QUANTITATIVE SENSORY TESTING; SEDATION; SIGNAL TRANSDUCTION; SOMNOLENCE; SPINAL CORD DORSAL HORN; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; XEROSTOMIA;

DIABETIC NEUROPATHIES; GAMMA-AMINOBUTYRIC ACID; HUMANS; PAIN; PERIPHERAL NERVOUS SYSTEM DISEASES; THIOPHENES;

EID: 84891809070     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-1964     Document Type: Article

References (81)

1. Boulton AJM, Malik RA, Arezzo JC, Sosenko JM. Diabetic somatic neuropathies. Diabetes Care 2004;27: 1458-1486
2. Tesfaye S, Boulton AJM, Dyck PJ, et al.; Toronto Diabetic Neuropathy Expert Group. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010;33: 2285-2293
3. Zelman DC, Brandenburg NA, Gore M. Sleep impairment in patients with painful diabetic peripheral neuropathy. Clin J Pain 2006;22: 681-685
4. Gore M, Brandenburg NA, Dukes E, Hoffman DL, Tai KS, Stacey B. Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. J Pain SymptomManage 2005;30: 374-385
5. Boulton AJM, Armstrong WD, Scarpello JHB, Ward JD. The natural history of painful diabetic neuropathyda 4-year study. Postgrad Med J 1983;59: 556-559
6. Benbow SJ, Chan AW, Bowsher D, MacFarlane IA, Williams G. A prospective study of painful symptoms, small-fibre function and peripheral vascular disease in chronic painful diabetic neuropathy. Diabet Med 1994;11: 17-21
7. Abbott CA, Malik RA, van Ross ER, Kulkarni J, Boulton AJ. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes Care 2011; 34: 2220-2224
8. Daousi C, McFarlane IA, Woodward A, Nurmikko TJ, Bendred PE, Benbow SJ. Chronic painful peripheral neuropathy in an urban community: a control comparison of people with and without diabetes. Diabet Med 2004;21: 976-982
9. Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care 2006;29: 1518-1522
10. Tesfaye S, Chaturvedi N, Eaton SEM, et al.; EURODIAB Prospective Complications Study Group. Vascular risk factors and diabetic neuropathy. N Engl J Med 2005;352: 341-350
11. Ziegler D, Rathmann W, Dickhaus T, Meisinger C, Mielck A; KORA Study Group. Neuropathic pain in diabetes, prediabetes and normal glucose tolerance: the MONICA/KORA Augsburg Surveys S2 and S3. Pain Med 2009;10: 393-400
12. Van Acker K, Bouhassira D, De Bacquer D, et al. Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics. Diabetes Metab 2009; 35: 206-213
13. Ziegler D, Rathmann W, Meisinger C, Dickhaus T, Mielck A;KORA StudyGroup. Prevalence and risk factors of neuropathic pain in survivors of myocardial infarction with pre-diabetes and diabetes. The KORA Myocardial Infarction Registry. Eur J Pain 2009;13: 582-587
14. Boulton AJ, Vinik AI, Arezzo JC, et al.; American Diabetes Association. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005; 28: 956-962
15. Vinik AI, Erbas T, Park TS, Pierce KK, Stansberry KB. Methods for evaluation of peripheral neurovascular dysfunction. Diabetes Technol Ther 2001;3: 29-50
16. Malik R, Veves A, Tesfaye S, et al.; on behalf of the Toronto Consensus Panel on Diabetic Neuropathy. Small fiber neuropathy: role in the diagnosis of diabetic sensorimotor polyneuropathy. Diabetes Metab Res Rev 2011;27: 678-684
17. Rolke R, Baron R, Maier C, et al. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): standardized protocol and reference values. Pain 2006;123: 231-243
18. RagéM, Van Acker N, Knaapen MW, et al. Asymptomatic small fiber neuropathy in diabetes mellitus: investigations with intraepidermal nerve fiber density, quantitative sensory testing and laser-evoked potentials. J Neurol 2011;258: 1852-1864
19. Chao C-C, Tseng MT, Lin YJ, et al. Pathophysiology of neuropathic pain in type 2 diabetes: skin denervation and contact heat-evoked potentials. Diabetes Care 2010;33: 2654-2659
20. Young MJ, Boulton AJM, MacLeod AF, Williams DR, Sonksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993;36: 150-154
21. Bril V, Perkins BA. Validation of the Toronto Clinical Scoring System for diabetic polyneuropathy. Diabetes Care 2002;25: 2048-2052
22. Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care 1994;17: 1281-1289
23. Dyck PJ. Detection, characterization, and staging of polyneuropathy: assessed in diabetics. Muscle Nerve 1988;11: 21-32
24. Dyck PJ, Overland CJ, Low PA, et al. Signs and symptoms versus nerve conduction studies to diagnose diabetic sensorimotor polyneuropathy: Cl vs. NPhys trial. Muscle Nerve 2010;42: 157-164
25. Cruccu G, Sommer C, Anand P, et al. EFNS guidelines on neuropathic pain assessment: revised 2009. Eur J Neurol 2010;17: 1010-1018
26. Zelman DC, Gore M, Dukes E, Tai KS, Brandenburg N. Validation of a modified version of the brief pain inventory for painful diabetic peripheral neuropathy. J Pain Symptom Manage 2005;29: 401-410
27. Bouhassira D, Attal N, Fermanian J, et al. Development and validation of the Neuropathic Pain Symptom Inventory. Pain 2004;108: 248-257
28. Backonja MM, Krause SJ. Neuropathic pain questionnairedshort form. Clin J Pain 2003;19: 315-316
29. Bennett M. The LANSS Pain Scale: the Leeds assessment of neuropathic symptoms and signs. Pain 2001;92: 147-157
30. Freynhagen R, Baron R, Gockel U, Tölle TR. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin 2006;22: 1911-1920
31. Melzack R. The short-form McGill pain questionnaire. Pain 1987;30: 191-197
32. Vileikyte L, Peyrot M, Bundy C, et al. The development and validation of a neuropathy- and foot ulcer-specific quality of life instrument. Diabetes Care 2003;26: 2549-2555
33. Vinik EJ, Hayes RP, Oglesby A, et al. The development and validation of the Norfolk QOL-DN, a new measure of patients' perception of the effects of diabetes and diabetic neuropathy. Diabetes Technol Ther 2005;7: 497-508
34. Vinik A. The approach to themanagement of the patient with neuropathic pain. J Clin Endocrinol Metab 2010;95: 4802-4811
35. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67: 361-370
36. Beck AT, Steer RA, Brown GK. Manual for the Beck Depression Inventory-II. San Antonio, TX, Psychological Corporation, 1996, p. 38
37. Tesfaye S, Kempler P. Painful diabetic neuropathy. Diabetologia 2005;48: 805-807
38. Oyibo SO, Prasad YDM, Jackson NJ, Jude EB, Boulton AJ. The relationship between blood glucose excursions and painful diabetic peripheral neuropathy: a pilot study. Diabet Med 2002;19: 870-873
39. Eaton SE, Harris ND, Ibrahim S, et al. Increased sural nerve epineurial blood flow in human subjects with painful diabetic neuropathy.Diabetologia 2003;46: 934-939
40. Quattrini C, Harris ND, Malik RA, Tesfaye S. Impaired skin microvascular reactivity in painful diabetic neuropathy. Diabetes Care 2007;30: 655-659
41. Sorensen L, Molyneaux L, Yue DK. The relationship among pain, sensory loss, and small nerve fibers in diabetes.DiabetesCare 2006;29: 883-887
42. Selvarajah D, Wilkinson ID, Gandhi R, Griffiths PD, Tesfaye S. Microvascular perfusion abnormalities of the Thalamus in painful but not painless diabetic polyneuropathy: a clue to the pathogenesis of pain in type 1 diabetes. Diabetes Care 2011;34: 718-720
43. Gandhi RA, Marques JLB, Selvarajah D, Emery CJ, Tesfaye S. Painful diabetic neuropathy is associated with greater autonomic dysfunction than painless diabetic neuropathy. Diabetes Care 2010; 33: 1585-1590
44. Maier C, Baron R, Tölle TR, et al. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): somatosensory abnormalities in 1236 patients with different neuropathic pain syndromes. Pain 2010;150: 439-450
45. Venkatachalam K, Montell C. TRP channels. Annu Rev Biochem 2007;76: 387-417
46. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997; 389: 816-824
47. Colburn RW, Lubin ML, Stone DJ Jr, et al. Attenuated cold sensitivity in TRPM8 null mice. Neuron 2007;54: 379-386
48. Binder A, May D, Baron R, et al. Transient receptor potential channel polymorphisms are associated with the somatosensory function in neuropathic pain patients. PLoS One 2011; 6:e17387
49. Honore P, Kage K, Mikusa J, et al. Analgesic profile of intrathecal P2X(3) antisense oligonucleotide treatment in chronic inflammatory and neuropathic pain states in rats. Pain 2002;99: 11-19
50. Dickenson AH, Matthews EA, Suzuki R. Neurobiology of neuropathic pain: mode of action of anticonvulsants. Eur J Pain 2002;6(Suppl. A): 51-60
51. Yang Y, Wang Y, Li S, et al. Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia. J Med Genet 2004;41: 171-174
52. Cox JJ, Reimann F, Nicholas AK, et al. An SCN9A channelopathy causes congenital inability to experience pain. Nature 2006; 444: 894-898
53. Reimann F, Cox JJ, Belfer I, et al. Pain perception is altered by a nucleotide polymorphism in SCN9A. Proc Natl Acad Sci USA 2010;107: 5148-5153
54. Harvey VL, Dickenson AH. Mechanisms of pain in nonmalignant disease. Curr Opin Support Palliat Care 2008;2: 133-139
55. Bierhaus A, Fleming T, Stoyanov S, et al. Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. Nat Med 2012;18: 926-933
56. Blackburn-Munro G, Jensen BS. The anticonvulsant retigabine attenuates nociceptive behaviours in rat models of persistent and neuropathic pain. Eur J Pharmacol 2003;460: 109-116
57. Passmore GM, Selyanko AA, Mistry M, et al. KCNQ/M currents in sensory neurons: significance for pain therapy. J Neurosci 2003;23: 7227-7236
58. Harris JA, Murphy JA. Retigabine (ezogabine) as add-on therapy for partial-onset seizures: an update for clinicians. Ther Adv Chronic Dis 2011;2: 371-376
59. Bauer CS, Nieto-Rostro M, Rahman W, et al. The increased trafficking of the calcium channel subunit alpha2delta-1 to presynaptic terminals in neuropathic pain is inhibited by the alpha2delta ligand pregabalin. J Neurosci 2009;29: 4076-4088
60. Bannister K, Bee LA, Dickenson AH. Preclinical and early clinical investigations related to monoaminergic pain modulation. Neurotherapeutics 2009;6: 703-712
61. D'Mello R, Dickenson AH. Spinal cord mechanisms of pain. Br J Anaesth 2008; 101: 8-16
62. Bee LA, Bannister K, Rahman W, Dickenson AH. Mu-opioid and noradrenergic a(2)- adrenoceptor contributions to the effects of tapentadol on spinal electrophysiological measures of nociception in nerve-injured rats. Pain 2011;152: 131-139
63. De Felice M, Sanoja R, Wang R, et al. Engagement of descending inhibition from the rostral ventromedial medulla protects against chronic neuropathic pain. Pain 2011;152: 2701-2709
64. Ziegler D. Current concepts in the management of diabetic polyneuropathy. Curr Diabetes Rev 2011;7: 208-220
65. Tesfaye S, Vileikyte L, Rayman G, et al.; Toronto Expert Panel on Diabetic Neuropathy. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes Metab Res Rev 2011;27: 629-638
66. Kajdasz DK, Iyengar S, Desaiah D, et al. Duloxetine for the management of diabetic peripheral neuropathic pain: evidencebased findings from post hoc analysis of three multicenter, randomized, doubleblind, placebo-controlled, parallel-group studies. Clin Ther 2007;29(Suppl.): 2536-2546
67. Rowbotham MC, Goli V, Kunz NR, Lei D. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain 2004;110: 697-706
68. Backonja MM, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998;280: 1831-1836
69. Freeman R, Durso-Decruz E, Emir B. Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. Diabetes Care 2008;31: 1448-1454
70. Ziegler D, Nowak H, Kempler P, Vargha P, Low PA. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med 2004;21: 114-121
71. Attal N, Cruccu G, Baron R, et al.; European Federation of Neurological Societies. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010;17:1113-e88
72. NICE Clinical Guideline 96: Neuropathic Pain. The pharmacological management of neuropathic pain in adults in non-specialist settings.March 2010. Available from www.nice.org.uk
73. Bril V, England J, Franklin GM, et al.; American Academy of Neurology; American Association of Neuromuscular and Electrodiagnostic Medicine; American Academy of Physical Medicine and Rehabilitation. Evidence-based guideline: Treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2011;76: 1758-1765
74. Vorobeychik Y, Gordin V, Mao J, Chen L. Combination therapy for neuropathic pain: a review of current evidence. CNS Drugs 2011;25: 1023-1034
75. O'Connor AB, Dworkin RH. Treatment of neuropathic pain: an overview of recent guidelines. Am J Med 2009;122(Suppl.): S22-S32
76. Bansal D, Bhansali A, Hota D, Chakrabarti A, Dutta P. Amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double blind clinical trial. Diabet Med 2009;26: 1019-1026
77. Kaur H, Hota D, Bhansali A, Dutta P, Bansal D, Chakrabarti A. A comparative evaluation of amitriptyline and duloxetine in painful diabetic neuropathy: a randomized, double-blind, cross-over clinical trial. Diabetes Care 2011;34: 818-822
78. Quilici S, Chancellor J, Löthgren M, et al. Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain. BMC Neurol 2009;9:6
79. Gilron I, Bailey JM, Tu D, Holden RR, Jackson AC, Houlden RL. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. Lancet 2009;374: 1252-1261
80. Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlden RL. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005;352: 1324-1334
81. Tesfaye S, Wilhelm S, Lledo A, et al. Duloxetine and pregabalin: high-dose monotherapy or their combination? The "COMBO-DN study" - a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain. Pain. 31May 2013 [Epub ahead of print]